Treatment Intensity Should Be Personalized in Women with HER2-positive Breast Cancer, Study Says

Treatment Intensity Should Be Personalized in Women with HER2-positive Breast Cancer, Study Says
Personalized treatment intensity is crucial to the success of less toxic and demanding therapies for women with HER2-positive breast cancer, according to a spokesperson from the European Society for Medical Oncology (ESMO). The remarks by Carmen Criscitiello, MD, PhD, accompanied updated results from the PERNETTA trial (EudraCT number 2012-002556-17), a study assessing the consequences of removing chemotherapy as a first-line treatment for women with HER2-positive breast cancer. The presentation was made at the ESMO Breast Cancer Congress 2019, May 2–4 in Berlin, Germany. The findings of the study, "Pertuzumab (P) + trastuzumab (T) with or without chemotherapy both followed by T-DM1 in case of progression in patients with HER2-positive metastatic breast cancer (MBC) - The PERNETTA trial (SAKK 22/10), a randomized open label phase II study (SAKK, UNICANCER, BOOG)," were presented by Jens Huober, MD, a professor at the University Hospital Ulm in Germany. "The introduction of anti-HER2 therapies has brought a huge survival benefit in early and advanced HER2 positive breast cancer, thu
Subscribe or to access all post and page content.